Colorectal cancer and gut microbiota studies in China

References

• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. A Cancer J Clin. 2021;71(3):209–24. doi:10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Xia C, Dong X, Li H, Cao M, Sun D, He S, Yang F, Yan X, Zhang S, Li N, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J. 2022;135(5):584–590. doi:10.1097/CM9.0000000000002108.
   PubMed Web of Science ®Google Scholar
• Li N, Lu B, Luo C, Cai J, Lu M, Zhang Y, Chen H, Dai M. Incidence, mortality, survival, risk factor and screening of colorectal cancer: a comparison among China, Europe, and northern America. Cancer Lett. 2021;522:255–268. doi:10.1016/j.canlet.2021.09.034.
   PubMed Web of Science ®Google Scholar
• Zheng X, Hur J, Nguyen LH, Liu J, Song M, Wu K, Smith-Warner SA, Ogino S, Willett WC, Chan AT, et al. Comprehensive assessment of diet quality and risk of precursors of early-onset colorectal cancer. J Natl Cancer Inst. 2021;113(5):543–552. doi:10.1093/jnci/djaa164.
   PubMedGoogle Scholar
• Dai Z, Coker OO, Nakatsu G, Wu WKK, Zhao L, Chen Z, Chan FKL, Kristiansen K, Sung JJY, Wong SH, et al. Multi-cohort analysis of colorectal cancer metagenome identified altered bacteria across populations and universal bacterial markers. Microbiome. 2018;6(1):70. doi:10.1186/s40168-018-0451-2.
   PubMed Web of Science ®Google Scholar
• Wong SH, Yu J. Gut microbiota in colorectal cancer: mechanisms of action and clinical applications. Nat Rev Gastroenterol Hepatol. 2019;16(11):690–704. doi:10.1038/s41575-019-0209-8.
   PubMed Web of Science ®Google Scholar
• Liu W, Zhang X, Xu H, Li S, Lau HC, Chen Q, Zhang B, Zhao L, Chen H, Sung JJ, et al. Microbial community heterogeneity within colorectal neoplasia and its correlation with colorectal carcinogenesis. Gastroenterol. 2021;160(7):2395–2408. doi:10.1053/j.gastro.2021.02.020.
   PubMed Web of Science ®Google Scholar
• Feng Q, Liang S, Jia H, Stadlmayr A, Tang L, Lan Z, Zhang D, Xia H, Xu X, Jie Z, et al. Gut microbiome development along the colorectal adenoma–carcinoma sequence. Nat Commun. 2015;6(1):6528. doi:10.1038/ncomms7528.
   PubMed Web of Science ®Google Scholar
• Liu NN, Jiao N, Tan JC, Wang Z, Wu D, Wang AJ, Chen J, Tao L, Zhou C, Fang W, et al. Multi-kingdom microbiota analyses identify bacterial–fungal interactions and biomarkers of colorectal cancer across cohorts. Nature Microbiol. 2022;7(2):238–250. doi:10.1038/s41564-021-01030-7.
   PubMed Web of Science ®Google Scholar
• Xie YH, Gao QY, Cai GX, Sun XM, Sun XM, Zou TH, Chen HM, Yu SY, Qiu YW, Gu WQ, et al. Fecal clostridium symbiosum for noninvasive detection of early and advanced colorectal cancer: test and validation studies. EBioMed. 2017;25:32–40. doi:10.1016/j.ebiom.2017.10.005.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yu X, Yu E, Wang N, Cai Q, Shuai Q, Yan F, Jiang L, Wang H, Liu J, et al. Changes in gut microbiota and plasma inflammatory factors across the stages of colorectal tumorigenesis: a case-control study. BMC Microbiol. 2018;18(1):92. doi:10.1186/s12866-018-1232-6.
   PubMed Web of Science ®Google Scholar
• Yu J, Feng Q, Wong SH, Zhang D, Liang QY, Qin Y, Tang L, Zhao H, Stenvang J, Li Y, et al. Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. Gut. 2017;66(1):70–78. doi:10.1136/gutjnl-2015-309800.
   PubMed Web of Science ®Google Scholar
• Li N, Bai C, Zhao L, Ge Y, Li X. Characterization of the fecal microbiota in gastrointestinal cancer patients and healthy people. Clin Transl Oncol. 2022;24(6):1134–1147. doi:10.1007/s12094-021-02754-y.
   PubMed Web of Science ®Google Scholar
• Chen Q, Xu L, Wu T, Li J, Hua L. Analysis of abnormal intestinal flora on risk of intestinal cancer and effect of heparin on formation of bacterial biofilm. Bioengineered. 2022;13(1):894–904. doi:10.1080/21655979.2021.2014388.
   PubMed Web of Science ®Google Scholar
• Yuan D, Tao Y, Wang H, Wang J, Cao Y, Cao W, Pan S, Yu Z. A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer. Invest New Drugs. 2022;40(5):884–894. doi:10.1007/s10637-022-01263-1.
   PubMed Web of Science ®Google Scholar
• Chang H, Mishra R, Cen C, Tang Y, Ma C, Wasti S, Wang Y, Ou Q, Chen K, Zhang J. Metagenomic analyses expand bacterial and functional profiling biomarkers for colorectal cancer in a Hainan Cohort, China. Curr Microbiol. 2021;78(2):705–712. doi:10.1007/s00284-020-02299-3.
   PubMed Web of Science ®Google Scholar
• Du X, Li Q, Tang Z, Yan L, Zhang L, Zheng Q, Zeng X, Chen G, Yue H, Li J, et al. Alterations of the gut microbiome and fecal metabolome in colorectal cancer: Implication of intestinal metabolism for tumorigenesis. Front Physiol. 2022;13:854545. doi:10.3389/fphys.2022.854545.
   PubMed Web of Science ®Google Scholar
• Coker OO, Liu C, Wu WKK, Wong SH, Jia W, Sung JJY, Yu J. Altered gut metabolites and microbiota interactions are implicated in colorectal carcinogenesis and can be non-invasive diagnostic biomarkers. Microbiome. 2022;10(1):35. doi:10.1186/s40168-021-01208-5.
   PubMed Web of Science ®Google Scholar
• Yeoh YK, Chen Z, Wong MCS, Hui M, Yu J, Ng SC, Sung JJY, Chan FKL, Chan PKS. Southern Chinese populations harbour non-nucleatum Fusobacteria possessing homologues of the colorectal cancer-associated FadA virulence factor. Gut. 2020;69(11):1998–2007. doi:10.1136/gutjnl-2019-319635.
   PubMed Web of Science ®Google Scholar
• Yang J, Li D, Yang Z, Dai W, Feng X, Liu Y, Jiang Y, Li P, Li Y, Tang B, et al. Establishing high-accuracy biomarkers for colorectal cancer by comparing fecal microbiomes in patients with healthy families. Gut Microbes. 2020;11(4):918–929. doi:10.1080/19490976.2020.1712986.
   PubMed Web of Science ®Google Scholar
• Li Y, Cao H, Fei B, Gao Q, Yi W, Han W, Bao C, Xu J, Zhao W, Zhang F. Gut microbiota signatures in tumor, para-cancerous, normal mucosa, and feces in colorectal cancer patients. Front Cell Dev Biol. 2022;10:916961. doi:10.3389/fcell.2022.916961.
   PubMed Web of Science ®Google Scholar
• Hua H, Sun Y, He X, Chen Y, Teng L, Lu C. Intestinal microbiota in colorectal adenoma-carcinoma sequence. Front Med. 2022;9:888340. doi:10.3389/fmed.2022.888340.
   Web of Science ®Google Scholar
• Gao R, Wu C, Zhu Y, Kong C, Zhu Y, Gao Y, Zhang X, Yang R, Zhong H, Xiong X, et al. Integrated analysis of colorectal cancer reveals cross-cohort gut microbial signatures and associated serum metabolites. Gastroenterology. 2022;163(4):1024–37.e9. doi:10.1053/j.gastro.2022.06.069.
   PubMed Web of Science ®Google Scholar
• Wu Y, Jiao N, Zhu R, Zhang Y, Wu D, Wang AJ, Fang S, Tao L, Li Y, Cheng S, et al. Identification of microbial markers across populations in early detection of colorectal cancer. Nat Commun. 2021;12(1):3063. doi:10.1038/s41467-021-23265-y.
   PubMed Web of Science ®Google Scholar
• Jin Y, Liu Y, Zhao L, Zhao F, Feng J, Li S, Chen H, Sun J, Zhu B, Geng R, et al. Gut microbiota in patients after surgical treatment for colorectal cancer. Environ Microbiol. 2019;21(2):772–783. doi:10.1111/1462-2920.14498.
   PubMed Web of Science ®Google Scholar
• Huang R, He K, Duan X, Xiao J, Wang H, Xiang G. Changes of intestinal microflora in colorectal cancer patients after surgical resection and chemotherapy. Comput Math Methods Med. 2022;2022:1940846. doi:10.1155/2022/1940846.
   PubMed Web of Science ®Google Scholar
• Huo RX, Wang YJ, Hou SB, Wang W, Zhang CZ, Wan XH. Gut mucosal microbiota profiles linked to colorectal cancer recurrence. World J Gastroenterol. 2022;28(18):1946–1964. doi:10.3748/wjg.v28.i18.1946.
   PubMed Web of Science ®Google Scholar
• Nakatsu G, Li X, Zhou H, Sheng J, Wong SH, Wu WK, Ng SC, Tsoi H, Dong Y, Zhang N, et al. Gut mucosal microbiome across stages of colorectal carcinogenesis. Nat Commun. 2015;6:8727. doi:10.1038/ncomms9727.
   PubMed Web of Science ®Google Scholar
• Xu Z, Lv Z, Chen F, Zhang Y, Xu Z, Huo J, Liu W, Yu S, Tuersun A, Zhao J, et al. Dysbiosis of human tumor microbiome and aberrant residence of Actinomyces in tumor-associated fibroblasts in young-onset colorectal cancer. Front Immunol. 2022;13:1008975. doi:10.3389/fimmu.2022.1008975.
   PubMed Web of Science ®Google Scholar
• Yang Y, Du L, Shi D, Kong C, Liu J, Liu G, Li X, Ma Y. Dysbiosis of human gut microbiome in young-onset colorectal cancer. Nat Commun. 2021;12(1):6757. doi:10.1038/s41467-021-27112-y.
   PubMed Web of Science ®Google Scholar
• Zhong M, Xiong Y, Ye Z, Zhao J, Zhong L, Liu Y, Zhu Y, Tian L, Qiu X, Hong X. Microbial community profiling distinguishes left-sided and right-sided colon cancer. Front Cell Infect Microbiol. 2020;10:498502. doi:10.3389/fcimb.2020.498502.
   PubMed Web of Science ®Google Scholar
• Yachida S, Mizutani S, Shiroma H, Shiba S, Nakajima T, Sakamoto T, Watanabe H, Masuda K, Nishimoto Y, Kubo M, et al. Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer. Nat Med. 2019;25(6):968–976. doi:10.1038/s41591-019-0458-7.
   PubMed Web of Science ®Google Scholar
• Iliev ID, Leonardi I. Fungal dysbiosis: immunity and interactions at mucosal barriers. Nat Rev Immunol. 2017;17(10):635–646. doi:10.1038/nri.2017.55.
   PubMed Web of Science ®Google Scholar
• Richard ML, Sokol H. The gut mycobiota: insights into analysis, environmental interactions and role in gastrointestinal diseases. Nat Rev Gastro Hepat. 2019;16(6):331–345. doi:10.1038/s41575-019-0121-2.
   PubMed Web of Science ®Google Scholar
• Lin Y, Lau HC, Liu Y, Kang X, Wang Y, Ting NL, Kwong TN, Han J, Liu W, Liu C, et al. Altered mycobiota signatures and enriched pathogenic aspergillus rambelli are associated with colorectal cancer based on multicohort fecal metagenomic analyses. Gastroenterology. 2022;163(4):908–921. doi:10.1053/j.gastro.2022.06.038.
   PubMed Web of Science ®Google Scholar
• Coker OO, Nakatsu G, Dai RZ, Wu WKK, Wong SH, Ng SC, Chan FKL, Sung JJY, Yu J. Enteric fungal microbiota dysbiosis and ecological alterations in colorectal cancer. Gut. 2019;68(4):654–662. doi:10.1136/gutjnl-2018-317178.
   PubMed Web of Science ®Google Scholar
• Gao R, Xia K, Wu M, Zhong H, Sun J, Zhu Y, Huang L, Wu X, Yin L, Yang R, et al. Alterations of gut mycobiota profiles in adenoma and colorectal cancer. Front Cell Infect Microbiol. 2022;12:839435. doi:10.3389/fcimb.2022.839435.
   PubMed Web of Science ®Google Scholar
• Chen X, Fruehauf J, Goldsmith JD, Xu H, Katchar KK, Koon HW, Zhao D, Kokkotou EG, Pothoulakis C, Kelly CP. Saccharomyces boulardii inhibits EGF receptor signaling and intestinal tumor growth in Apc(min) mice. Gastroenterology. 2009;137(3):914–923. doi:10.1053/j.gastro.2009.05.050.
   PubMed Web of Science ®Google Scholar
• Wang T, Fan C, Yao A, Xu X, Zheng G, You Y, Jiang C, Zhao X, Hou Y, Hung MC, et al. The adaptor protein CARD9 protects against colon cancer by restricting mycobiota-mediated expansion of myeloid-derived suppressor cells. Immunity. 2018;49(3):504–14.e4. doi:10.1016/j.immuni.2018.08.018.
   PubMed Web of Science ®Google Scholar
• Zuo W, Michail S, Sun F. Metagenomic analyses of multiple gut datasets revealed the association of phage signatures in colorectal cancer. Frontiers Cellular Infect Microbiol. 2022;12:918010. doi:10.3389/fcimb.2022.918010.
   PubMed Web of Science ®Google Scholar
• Nakatsu G, Zhou H, Wu WKK, Wong SH, Coker OO, Dai Z, Li X, Szeto CH, Sugimura N, Lam TY, et al. Alterations in enteric virome are associated with colorectal cancer and survival outcomes. Gastroenterology. 2018;155(2):529–41.e5. doi:10.1053/j.gastro.2018.04.018.
   PubMed Web of Science ®Google Scholar
• Gao R, Zhu Y, Kong C, Xia K, Li H, Zhu Y, Zhang X, Liu Y, Zhong H, Yang R, et al. Alterations, interactions, and diagnostic potential of gut bacteria and viruses in colorectal cancer. Front Cell Infect Microbiol. 2021;11:657867. doi:10.3389/fcimb.2021.657867.
   PubMed Web of Science ®Google Scholar
• Chen F, Li S, Guo R, Song F, Zhang Y, Wang X, Huo X, Lv Q, Ullah H, Wang G, et al. Meta-analysis of fecal viromes demonstrates high diagnostic potential of the gut viral signatures for colorectal cancer and adenoma risk assessment. J Adv Res. 2022;49:103–114. doi:10.1016/j.jare.2022.09.012.
   PubMed Web of Science ®Google Scholar
• Shen S, Huo D, Ma C, Jiang S, Zhang J, Xu ZZ. Expanding the colorectal cancer biomarkers based on the human gut phageome. Microbiol Spectr. 2021;9(3):e0009021. doi:10.1128/Spectrum.00090-21.
   PubMed Web of Science ®Google Scholar
• Dong X, Pan P, Zheng DW, Bao P, Zeng X, Zhang XZ. Bioinorganic hybrid bacteriophage for modulation of intestinal microbiota to remodel tumor-immune microenvironment against colorectal cancer. Sci Adv. 2020;6(20):eaba1590. doi:10.1126/sciadv.aba1590.
   PubMed Web of Science ®Google Scholar
• Yang J, Wei H, Zhou Y, Szeto CH, Li C, Lin Y, Coker OO, Lau HCH, Chan AWH, Sung JJY, et al. High-fat diet promotes colorectal tumorigenesis through modulating gut microbiota and metabolites. Gastroenterology. 2022;162(1):135–49.e2. doi:10.1053/j.gastro.2021.08.041.
   PubMed Web of Science ®Google Scholar
• Chen D, Jin D, Huang S, Wu J, Xu M, Liu T, Dong W, Liu X, Wang S, Zhong W, et al. Clostridium butyricum, a butyrate-producing probiotic, inhibits intestinal tumor development through modulating Wnt signaling and gut microbiota. Cancer Lett. 2020;469:456–467. doi:10.1016/j.canlet.2019.11.019.
   PubMed Web of Science ®Google Scholar
• Hou H, Chen D, Zhang K, Zhang W, Liu T, Wang S, Dai X, Wang B, Zhong W, Cao H. Gut microbiota-derived short-chain fatty acids and colorectal cancer: Ready for clinical translation? Cancer Lett. 2022;526:225–235. doi:10.1016/j.canlet.2021.11.027.
   PubMed Web of Science ®Google Scholar
• Keane JM, Joyce SA, Gahan CGM, Hyland NP, Houston A. Microbial metabolites as molecular mediators of host-microbe symbiosis in colorectal cancer. Results Probl Cell Differ. 2020;69:581–603. doi:10.1007/978-3-030-51849-3_22.
   PubMedGoogle Scholar
• Ryu TY, Kim K, Son MY, Min JK, Kim J, Han TS, Kim DS, Cho HS. Downregulation of PRMT1, a histone arginine methyltransferase, by sodium propionate induces cell apoptosis in colon cancer. Oncol Rep. 2019;41(3):1691–1699. doi:10.3892/or.2018.6938.
   PubMed Web of Science ®Google Scholar
• Wang G, Yu Y, Wang YZ, Wang JJ, Guan R, Sun Y, Shi F, Gao J, Fu XL. Role of SCFAs in gut microbiome and glycolysis for colorectal cancer therapy. J Cell Physiol. 2019;234(10):17023–17049. doi:10.1002/jcp.28436.
   PubMed Web of Science ®Google Scholar
• Song M, Chan AT, Sun J. Influence of the gut microbiome, diet, and environment on risk of colorectal cancer. Gastroenterology. 2020;158(2):322–340. doi:10.1053/j.gastro.2019.06.048.
   PubMed Web of Science ®Google Scholar
• He Y, Fu L, Li Y, Wang W, Gong M, Zhang J, Dong X, Huang J, Wang Q, Mackay CR, et al. Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8(+) T cell immunity. Cell Metab. 2021;33(5):988–1000.e7. doi:10.1016/j.cmet.2021.03.002.
   PubMed Web of Science ®Google Scholar
• Ma X, Zhou Z, Zhang X, Fan M, Hong Y, Feng Y, Dong Q, Diao H, Wang G. Sodium butyrate modulates gut microbiota and immune response in colorectal cancer liver metastatic mice. Cell Biol Toxicol. 2020;36(5):509–515. doi:10.1007/s10565-020-09518-4.
   PubMed Web of Science ®Google Scholar
• Ridlon JM, Wolf PG, Gaskins HR. Taurocholic acid metabolism by gut microbes and colon cancer. Gut Microbes. 2016;7(3):201–215. doi:10.1080/19490976.2016.1150414.
   PubMed Web of Science ®Google Scholar
• Májer F, Sharma R, Mullins C, Keogh L, Phipps S, Duggan S, Kelleher D, Keely S, Long A, Radics G, et al. New highly toxic bile acids derived from deoxycholic acid, chenodeoxycholic acid and lithocholic acid. Bioorg Med Chem. 2014;22(1):256–268. doi:10.1016/j.bmc.2013.11.029.
   PubMed Web of Science ®Google Scholar
• Ma Y, Qu R, Zhang Y, Jiang C, Zhang Z, Fu W. Progress in the study of colorectal cancer caused by altered gut microbiota after cholecystectomy. Front Endocrinol (Lausanne). 2022;13:815999. doi:10.3389/fendo.2022.815999.
   PubMed Web of Science ®Google Scholar
• Cai J, Sun L, Gonzalez FJ. Gut microbiota-derived bile acids in intestinal immunity, inflammation, and tumorigenesis. Cell Host Microbe. 2022;30(3):289–300. doi:10.1016/j.chom.2022.02.004.
   PubMed Web of Science ®Google Scholar
• Attene-Ramos MS, Wagner ED, Gaskins HR, Plewa MJ. Hydrogen sulfide induces direct radical-associated DNA damage. Mol Cancer Res. 2007;5(5):455–459. doi:10.1158/1541-7786.MCR-06-0439.
   PubMed Web of Science ®Google Scholar
• Guo FF, Yu TC, Hong J, Fang JY. Emerging roles of hydrogen sulfide in inflammatory and neoplastic colonic diseases. Front Physiol. 2016;7:156. doi:10.3389/fphys.2016.00156.
   PubMed Web of Science ®Google Scholar
• O’Keefe SJ, Li JV, Lahti L, Ou J, Carbonero F, Mohammed K, Posma JM, Kinross J, Wahl E, Ruder E, et al. Fat, fibre and cancer risk in African Americans and rural Africans. Nat Commun. 2015;6:6342. doi:10.1038/ncomms7342.
   PubMed Web of Science ®Google Scholar
• Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet. 2019;394(10207):1467–1480. doi:10.1016/S0140-6736(19)32319-0.
   PubMed Web of Science ®Google Scholar
• Wong SH, Zhao L, Zhang X, Nakatsu G, Han J, Xu W, Xiao X, Kwong TNY, Tsoi H, Wu WKK, et al. Gavage of fecal samples from patients with colorectal cancer promotes intestinal carcinogenesis in germ-free and conventional mice. Gastroenterology. 2017;153(6):1621–33.e6. doi:10.1053/j.gastro.2017.08.022.
   PubMed Web of Science ®Google Scholar
• Yu YN, Fang JY. Gut microbiota and colorectal cancer. Gastrointestinal Tumors. 2015;2(1):26–32. doi:10.1159/000380892.
   PubMed Web of Science ®Google Scholar
• Tjalsma H, Boleij A, Marchesi JR, Dutilh BE. A bacterial driver-passenger model for colorectal cancer: beyond the usual suspects. Nat Rev Microbiol. 2012;10(8):575–582. doi:10.1038/nrmicro2819.
   PubMed Web of Science ®Google Scholar
• Li J, Ma X, Chakravarti D, Shalapour S, DePinho RA. Genetic and biological hallmarks of colorectal cancer. Genes Dev. 2021;35(11–12):787–820. doi:10.1101/gad.348226.120.
   PubMed Web of Science ®Google Scholar
• Kong C, Yan X, Zhu Y, Zhu H, Luo Y, Liu P, Ferrandon S, Kalady MF, Gao R, He J, et al. Fusobacterium nucleatum promotes the development of colorectal cancer by activating a cytochrome P450/epoxyoctadecenoic acid axis via TLR4/Keap1/NRF2 signaling. Cancer Res. 2021;81(17):4485–4498. doi:10.1158/0008-5472.Can-21-0453.
   PubMed Web of Science ®Google Scholar
• Rubinstein MR, Baik JE, Lagana SM, Han RP, Raab WJ, Sahoo D, Dalerba P, Wang TC, Han YW. Fusobacterium nucleatum promotes colorectal cancer by inducing Wnt/β-catenin modulator Annexin A1. EMBO Rep. 2019;20(4). doi:10.15252/embr.201847638.
   PubMed Web of Science ®Google Scholar
• Hong J, Guo F, Lu SY, Shen C, Ma D, Zhang X, Xie Y, Yan T, Yu T, Sun T, et al. F. Nucleatum targets lncRNA ENO1-IT1 to promote glycolysis and oncogenesis in colorectal cancer. Gut. 2021;70(11):2123–2137. doi:10.1136/gutjnl-2020-322780.
   PubMed Web of Science ®Google Scholar
• Yu T, Guo F, Yu Y, Sun T, Ma D, Han J, Qian Y, Kryczek I, Sun D, Nagarsheth N, et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell. 2017;170(3):548–63.e16. doi:10.1016/j.cell.2017.07.008.
   PubMed Web of Science ®Google Scholar
• Chen H, Tong T, Lu SY, Ji L, Xuan B, Zhao G, Yan Y, Song L, Zhao L, Xie Y, et al. Urea cycle activation triggered by host-microbiota maladaptation driving colorectal tumorigenesis. Cell Metab. 2023;35(4):651–666.e7. doi:10.1016/j.cmet.2023.03.003.
   PubMed Web of Science ®Google Scholar
• Zhao L, Zhang X, Zhou Y, Fu K, Lau HC, Chun TW, Cheung AH, Coker OO, Wei H, Wu WK, et al. Parvimonas micra promotes colorectal tumorigenesis and is associated with prognosis of colorectal cancer patients. Oncogene. 2022;41(36):4200–4210. doi:10.1038/s41388-022-02395-7.
   PubMed Web of Science ®Google Scholar
• Long X, Wong CC, Tong L, Chu ESH, Ho Szeto C, Go MYY, Coker OO, Chan AWH, Chan FKL, Sung JJY, et al. Peptostreptococcus anaerobius promotes colorectal carcinogenesis and modulates tumour immunity. Nature Microbiol. 2019;4(12):2319–2330. doi:10.1038/s41564-019-0541-3.
   PubMed Web of Science ®Google Scholar
• Chen S, Su T, Zhang Y, Lee A, He J, Ge Q, Wang L, Si J, Zhuo W, Wang L. Fusobacterium nucleatum promotes colorectal cancer metastasis by modulating KRT7-AS/KRT7. Gut Microbes. 2020;11(3):511–525. doi:10.1080/19490976.2019.1695494.
   PubMed Web of Science ®Google Scholar
• Xu C, Fan L, Lin Y, Shen W, Qi Y, Zhang Y, Chen Z, Wang L, Long Y, Hou T, et al. Fusobacterium nucleatum promotes colorectal cancer metastasis through miR-1322/CCL20 axis and M2 polarization. Gut Microbes. 2021;13(1):1980347. doi:10.1080/19490976.2021.1980347.
   PubMed Web of Science ®Google Scholar
• Sánchez-Alcoholado L, Ramos-Molina B, Otero A, Laborda-Illanes A, Ordóñez R, Medina JA, Gómez-Millán J, Queipo-Ortuño MI. The role of the gut microbiome in colorectal cancer development and therapy response. Cancers Basel. 2020;12(6):1406. doi:10.3390/cancers12061406.
   PubMed Web of Science ®Google Scholar
• Gur C, Ibrahim Y, Isaacson B, Yamin R, Abed J, Gamliel M, Enk J, Bar-On Y, Stanietsky-Kaynan N, Coppenhagen-Glazer S, et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity. 2015;42(2):344–355. doi:10.1016/j.immuni.2015.01.010.
   PubMed Web of Science ®Google Scholar
• Chung L, Thiele Orberg E, Geis AL, Chan JL, Fu K, DeStefano Shields CE, Dejea CM, Fathi P, Chen J, Finard BB, et al. Bacteroides fragilis toxin coordinates a pro-carcinogenic inflammatory cascade via targeting of colonic epithelial cells. Cell Host Microbe. 2018;23(2):203–14.e5. doi:10.1016/j.chom.2018.01.007.
   PubMed Web of Science ®Google Scholar
• Goodwin AC, Destefano Shields CE, Wu S, Huso DL, Wu X, Murray-Stewart TR, Hacker-Prietz A, Rabizadeh S, Woster PM, Sears CL, et al. Polyamine catabolism contributes to enterotoxigenic Bacteroides fragilis-induced colon tumorigenesis. Proc Natl Acad Sci U S A. 2011;108(37):15354–15359. doi:10.1073/pnas.1010203108.
   PubMed Web of Science ®Google Scholar
• Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology. 2008;135(4):1079–1099. doi:10.1053/j.gastro.2008.07.076.
   PubMed Web of Science ®Google Scholar
• CollectiveName:National Cancer Center CEGotDoCGftSED, Early Treatment of Colorectal C. [China guideline for the screening, early detection and early treatment of colorectal cancer (2020, Beijing)]. Zhonghua Zhong Liu Za Zhi. 2021;43(1):16–38. doi:10.3760/cma.j.cn112152-20210105-00010.
   PubMedGoogle Scholar
• Zhang J, Cheng Z, Ma Y, He C, Lu Y, Zhao Y, Chang X, Zhang Y, Bai Y, Cheng N. Effectiveness of screening modalities in colorectal cancer: a network meta-analysis. Clin Colorectal Cancer. 2017;16(4):252–263. doi:10.1016/j.clcc.2017.03.018.
   PubMed Web of Science ®Google Scholar
• Chen H, Li N, Ren J, Feng X, Lyu Z, Wei L, Li X, Guo L, Zheng Z, Zou S, et al. Participation and yield of a population-based colorectal cancer screening programme in China. Gut. 2019;68(8):1450–1457. doi:10.1136/gutjnl-2018-317124.
   PubMed Web of Science ®Google Scholar
• Zou J, Xiao Z, Wu Y, Yang J, Cui N. Noninvasive fecal testing for colorectal cancer. Clin Chim Acta. 2022;524:123–131. doi:10.1016/j.cca.2021.10.030.
   PubMed Web of Science ®Google Scholar
• Chen F, Dai X, Zhou CC, Li KX, Zhang YJ, Lou XY, Zhu YM, Sun YL, Peng BX, Cui W. Integrated analysis of the faecal metagenome and serum metabolome reveals the role of gut microbiome-associated metabolites in the detection of colorectal cancer and adenoma. Gut. 2022;71(7):1315–1325. doi:10.1136/gutjnl-2020-323476.
   PubMed Web of Science ®Google Scholar
• Liang Q, Chiu J, Chen Y, Huang Y, Higashimori A, Fang J, Brim H, Ashktorab H, Ng SC, Ng SSM, et al. Fecal bacteria act as novel biomarkers for noninvasive diagnosis of colorectal cancer. Clin Cancer Res. 2017;23(8):2061–2070. doi:10.1158/1078-0432.CCR-16-1599.
   PubMed Web of Science ®Google Scholar
• Guo S, Li L, Xu B, Li M, Zeng Q, Xiao H, Xue Y, Wu Y, Wang Y, Liu W, et al. A simple and novel fecal biomarker for colorectal cancer: Ratio of Fusobacterium nucleatum to probiotics populations, based on their antagonistic effect. Clin Chem. 2018;64(9):1327–1337. doi:10.1373/clinchem.2018.289728.
   PubMed Web of Science ®Google Scholar
• Wang N, Fang JY. Fusobacterium nucleatum, a key pathogenic factor and microbial biomarker for colorectal cancer. Trends Microbiol. 2022;31(2):159–172. doi:10.1016/j.tim.2022.08.010.
   PubMed Web of Science ®Google Scholar
• Mima K, Nishihara R, Qian ZR, Cao Y, Sukawa Y, Nowak JA, Yang J, Dou R, Masugi Y, Song M, et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut. 2016;65(12):1973–1980. doi:10.1136/gutjnl-2015-310101.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhang Y, Gui X, Zhang Y, Zhang Z, Chen W, Zhang X, Wang Y, Zhang M, Shang Z, et al. Salivary Fusobacterium nucleatum serves as a potential biomarker for colorectal cancer. iScience. 2022;25(5):104203. doi:10.1016/j.isci.2022.104203.
   PubMed Web of Science ®Google Scholar
• Liang JQ, Li T, Nakatsu G, Chen YX, Yau TO, Chu E, Wong S, Szeto CH, Ng SC, Chan FKL, et al. A novel faecal Lachnoclostridium marker for the non-invasive diagnosis of colorectal adenoma and cancer. Gut. 2020;69(7):1248–1257. doi:10.1136/gutjnl-2019-318532.
   PubMed Web of Science ®Google Scholar
• Wang HF, Li LF, Guo SH, Zeng QY, Ning F, Liu WL, Zhang G. Evaluation of antibody level against Fusobacterium nucleatum in the serological diagnosis of colorectal cancer. Sci Rep. 2016;6:33440. doi:10.1038/srep33440.
   PubMed Web of Science ®Google Scholar
• Shen X, Li J, Li J, Zhang Y, Li X, Cui Y, Gao Q, Chen X, Chen Y, Fang JY. Fecal enterotoxigenic bacteroides fragilis-peptostreptococcus stomatis-parvimonas micra biomarker for noninvasive diagnosis and prognosis of colorectal laterally spreading tumor. Front Oncol. 2021;11:661048. doi:10.3389/fonc.2021.661048.
   PubMed Web of Science ®Google Scholar
• Kong C, Liang L, Liu G, Du L, Yang Y, Liu J, Shi D, Li X, Ma Y. Integrated metagenomic and metabolomic analysis reveals distinct gut-microbiome-derived phenotypes in early-onset colorectal cancer. Gut. 2022;72(6):1129–1142. doi:10.1136/gutjnl-2022-327156.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Ma Y, Raoult D, Kroemer G, Gajewski TF. The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies. Sci. 2018;359(6382):1366–1370. doi:10.1126/science.aar6918.
   PubMed Web of Science ®Google Scholar
• Alexander JL, Wilson ID, Teare J, Marchesi JR, Nicholson JK, Kinross JM. Gut microbiota modulation of chemotherapy efficacy and toxicity. Nat Rev Gastro Hepat. 2017;14(6):356–365. doi:10.1038/nrgastro.2017.20.
   PubMed Web of Science ®Google Scholar
• Deng X, Li Z, Li G, Li B, Jin X, Lyu G. Comparison of microbiota in patients treated by surgery or chemotherapy by 16S rRNA sequencing reveals potential biomarkers for colorectal cancer therapy. Front Microbiol. 2018;9:1607. doi:10.3389/fmicb.2018.01607.
   PubMed Web of Science ®Google Scholar
• Yi Y, Shen L, Shi W, Xia F, Zhang H, Wang Y, Zhang J, Wang Y, Sun X, Zhang Z, et al. Gut microbiome components predict response to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: A prospective, longitudinal study. Clin Cancer Res. 2021;27(5):1329–1340. doi:10.1158/1078-0432.CCR-20-3445.
   PubMed Web of Science ®Google Scholar
• Li N, Bai C, Zhao L, Sun Z, Ge Y, Li X. The relationship between gut microbiome features and chemotherapy response in gastrointestinal cancer. Front Oncol. 2021;11:781697. doi:10.3389/fonc.2021.781697.
   PubMed Web of Science ®Google Scholar
• Wang F, He MM, Yao YC, Zhao X, Wang ZQ, Jin Y, Luo HY, Li JB, Wang FH, Qiu MZ, et al. Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis. Cell Rep Med. 2021;2(9):100383. doi:10.1016/j.xcrm.2021.100383.
   PubMedGoogle Scholar
• Bullman S, Pedamallu CS, Sicinska E, Clancy TE, Zhang X, Cai D, Neuberg D, Huang K, Guevara F, Nelson T, et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science (New York, NY). 2017;358(6369):1443–1448. doi:10.1126/science.aal5240.
   Google Scholar
• Al-Qadami G, Van Sebille Y, Le H, Bowen J. Gut microbiota: implications for radiotherapy response and radiotherapy-induced mucositis. Expert Rev Gastroenterol Hepatol. 2019;13(5):485–496. doi:10.1080/17474124.2019.1595586.
   PubMed Web of Science ®Google Scholar
• Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA, Molina DA, Salcedo R, Back T, Cramer S, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science (New York, NY). 2013;342(6161):967–970. doi:10.1126/science.1240527.
   Google Scholar
• Mármol I, Sánchez-de-Diego C, Pradilla Dieste A, Cerrada E, Rodriguez Yoldi MJ. Colorectal carcinoma: A general overview and future perspectives in colorectal cancer. Int J Mol Sci. 2017;18(1). doi:10.3390/ijms18010197.
   Web of Science ®Google Scholar
• Chang CW, Liu CY, Lee HC, Huang YH, Li LH, Chiau JC, Wang TE, Chu CH, Shih SC, Tsai TH, et al. Lactobacillus casei variety rhamnosus probiotic preventively attenuates 5-Fluorouracil/Oxaliplatin-induced intestinal injury in a syngeneic colorectal cancer model. Front Microbiol. 2018;9:983. doi:10.3389/fmicb.2018.00983.
   PubMed Web of Science ®Google Scholar
• Osterlund P, Ruotsalainen T, Korpela R, Saxelin M, Ollus A, Valta P, Kouri M, Elomaa I, Joensuu H. Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. Br J Cancer. 2007;97(8):1028–1034. doi:10.1038/sj.bjc.6603990.
   PubMed Web of Science ®Google Scholar
• Wallace BD, Wang H, Lane KT, Scott JE, Orans J, Koo JS, Venkatesh M, Jobin C, Yeh LA, Mani S, et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science (New York, NY). 2010;330(6005):831–835. doi:10.1126/science.1191175.
   Google Scholar
• Mego M, Chovanec J, Vochyanova-Andrezalova I, Konkolovsky P, Mikulova M, Reckova M, Miskovska V, Bystricky B, Beniak J, Medvecova L, et al. Prevention of irinotecan induced diarrhea by probiotics: A randomized double blind, placebo controlled pilot study. Complement Ther Med. 2015;23(3):356–362. doi:10.1016/j.ctim.2015.03.008.
   PubMed Web of Science ®Google Scholar
• Fan Q, Shang F, Chen C, Zhou H, Fan J, Yang M, Nie X, Liu L, Cai K, Liu H. Microbial characteristics of locally advanced rectal cancer patients after neoadjuvant chemoradiation therapy according to pathologic response. Cancer Manag Res. 2021;13:2655–2667. doi:10.2147/CMAR.S294936.
   PubMed Web of Science ®Google Scholar
• Dong J, Li Y, Xiao H, Zhang S, Wang B, Wang H, Li Y, Fan S, Cui M. Oral microbiota affects the efficacy and prognosis of radiotherapy for colorectal cancer in mouse models. Cell Rep. 2021;37(4):109886. doi:10.1016/j.celrep.2021.109886.
   PubMed Web of Science ®Google Scholar
• Wang Z, Wang Q, Wang X, Zhu L, Chen J, Zhang B, Chen Y, Yuan Z. Gut microbial dysbiosis is associated with development and progression of radiation enteritis during pelvic radiotherapy. J Cell Mol Med. 2019;23(5):3747–3756. doi:10.1111/jcmm.14289.
   PubMed Web of Science ®Google Scholar
• Cui M, Xiao H, Li Y, Zhou L, Zhao S, Luo D, Zheng Q, Dong J, Zhao Y, Zhang X, et al. Faecal microbiota transplantation protects against radiation-induced toxicity. EMBO Mol Med. 2017;9(4):448–461. doi:10.15252/emmm.201606932.
   PubMed Web of Science ®Google Scholar
• Crawford PA, Gordon JI. Microbial regulation of intestinal radiosensitivity. Proc Natl Acad Sci U S A. 2005;102(37):13254–13259. doi:10.1073/pnas.0504830102.
   PubMed Web of Science ®Google Scholar
• André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs P, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383(23):2207–2218. doi:10.1056/NEJMoa2017699.
   PubMed Web of Science ®Google Scholar
• Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36(8):773–779. doi:10.1200/JCO.2017.76.9901.
   PubMed Web of Science ®Google Scholar
• Chen EX, Jonker DJ, Loree JM, Kennecke HF, Berry SR, Couture F, Ahmad CE, Goffin JR, Kavan P, Harb M, et al. Effect of combined immune checkpoint inhibition vs best supportive care alone in patients with advanced colorectal cancer: The Canadian cancer trials group CO.26 study. JAMA Oncol. 2020;6(6):831–838. doi:10.1001/jamaoncol.2020.0910.
   PubMed Web of Science ®Google Scholar
• Xu X, Lv J, Guo F, Li J, Jia Y, Jiang D, Wang N, Zhang C, Kong L, Liu Y, et al. Gut microbiome influences the efficacy of PD-1 antibody immunotherapy on MSS-Type colorectal cancer via metabolic pathway. Front Microbiol. 2020;11:814. doi:10.3389/fmicb.2020.00814.
   PubMed Web of Science ®Google Scholar
• Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science (New York, NY). 2018;359(6371):97–103. doi:10.1126/science.aan4236.
   Google Scholar
• Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CP, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science (New York, NY). 2015;350(6264):1079–1084. doi:10.1126/science.aad1329.
   Google Scholar
• Dubin K, Callahan MK, Ren B, Khanin R, Viale A, Ling L, No D, Gobourne A, Littmann E, Huttenhower C, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun. 2016;7:10391. doi:10.1038/ncomms10391.
   PubMed Web of Science ®Google Scholar
• Huang J, Zheng X, Kang W, Hao H, Mao Y, Zhang H, Chen Y, Tan Y, He Y, Zhao W, et al. Metagenomic and metabolomic analyses reveal synergistic effects of fecal microbiota transplantation and anti-PD-1 therapy on treating colorectal cancer. Front Immunol. 2022;13:874922. doi:10.3389/fimmu.2022.874922.
   PubMed Web of Science ®Google Scholar
• Tanoue T, Morita S, Plichta DR, Skelly AN, Suda W, Sugiura Y, Narushima S, Vlamakis H, Motoo I, Sugita K, et al. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature. 2019;565(7741):600–605. doi:10.1038/s41586-019-0878-z.
   PubMed Web of Science ®Google Scholar
• Salminen S, Collado MC, Endo A, Hill C, Lebeer S, Quigley EMM, Sanders ME, Shamir R, Swann JR, Szajewska H, et al. The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. Nat Rev Gastro Hepat. 2021;18(9):649–667. doi:10.1038/s41575-021-00440-6.
   PubMed Web of Science ®Google Scholar
• Oh NS, Lee JY, Kim YT, Kim SH, Lee JH. Cancer-protective effect of a synbiotic combination between Lactobacillus gasseri 505 and a Cudrania tricuspidata leaf extract on colitis-associated colorectal cancer. Gut Microbes. 2020;12(1):1785803. doi:10.1080/19490976.2020.1785803.
   PubMed Web of Science ®Google Scholar
• Microecology CSo. Chinese expert consensus on the clinical application of microecological agents. Chin J Microecol. 2020;32(8):953–965.
   Google Scholar
• Kim CE, Yoon LS, Michels KB, Tranfield W, Jacobs JP, May FP. The impact of prebiotic, probiotic, and synbiotic supplements and yogurt consumption on the risk of colorectal neoplasia among adults: A systematic review. Nutrients. 2022;14(22). doi:10.3390/nu14224937.
   Web of Science ®Google Scholar
• Pala V, Sieri S, Berrino F, Vineis P, Sacerdote C, Palli D, Masala G, Panico S, Mattiello A, Tumino R, et al. Yogurt consumption and risk of colorectal cancer in the Italian European prospective investigation into cancer and nutrition cohort. Int J Cancer. 2011;129(11):2712–2719. doi:10.1002/ijc.26193.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ma C, Zhao J, Xu H, Hou Q, Zhang H. Lactobacillus casei Zhang and vitamin K2 prevent intestinal tumorigenesis in mice via adiponectin-elevated different signaling pathways. Oncotarget. 2017;8(15):24719–24727. doi:10.18632/oncotarget.15791.
   PubMedGoogle Scholar
• Xu H, Hiraishi K, Kurahara LH, Nakano-Narusawa Y, Li X, Hu Y, Matsuda Y, Zhang H, Hirano K. Inhibitory effects of breast milk-derived lactobacillus rhamnosus Probio-M9 on colitis-associated carcinogenesis by restoration of the gut microbiota in a mouse model. Nutrients. 2021;13(4). doi:10.3390/nu13041143.
   Web of Science ®Google Scholar
• Xie X, He Y, Li H, Yu D, Na L, Sun T, Zhang D, Shi X, Xia Y, Jiang T, et al. Effects of prebiotics on immunologic indicators and intestinal microbiota structure in perioperative colorectal cancer patients. Nutrition. 2019;61:132–142. doi:10.1016/j.nut.2018.10.038.
   PubMed Web of Science ®Google Scholar
• Chen Y, Qi A, Teng D, Li S, Yan Y, Hu S, Du X. Probiotics and synbiotics for preventing postoperative infectious complications in colorectal cancer patients: a systematic review and meta-analysis. Tech Coloproctol. 2022;26(6):425–436. doi:10.1007/s10151-022-02585-1.
   PubMed Web of Science ®Google Scholar
• Zhang JW, Du P, Gao J, Yang BR, Fang WJ, Ying CM. Preoperative probiotics decrease postoperative infectious complications of colorectal cancer. Am J Med Sci. 2012;343(3):199–205. doi:10.1097/MAJ.0b013e31823aace6.
   PubMed Web of Science ®Google Scholar
• Routy B, Gopalakrishnan V, Daillère R, Zitvogel L, Wargo JA, Kroemer G. The gut microbiota influences anticancer immunosurveillance and general health. Nat Rev Clin Oncol. 2018;15(6):382–396. doi:10.1038/s41571-018-0006-2.
   PubMed Web of Science ®Google Scholar
• Gao G, Ma T, Zhang T, Jin H, Li Y, Kwok LY, Zhang H, Sun Z. Adjunctive probiotic lactobacillus rhamnosus Probio-M9 administration enhances the effect of Anti-PD-1 antitumor therapy via restoring antibiotic-disrupted gut microbiota. Front Immunol. 2021;12:772532. doi:10.3389/fimmu.2021.772532.
   PubMed Web of Science ®Google Scholar
• Shi YC, Yang YS. Fecal microbiota transplantation: Current status and challenges in China. JGH open: an open access journal of gastroenterology and hepatology. 2018;2(4):114–116. doi:10.1002/jgh3.12071.
   Google Scholar
• Ren R, Gao X, Shi Y, Li J, Peng L, Sun G, Wang Z, Yan B, Zhi J, Yang Y. Long-term efficacy of low-intensity single donor fecal microbiota transplantation in ulcerative colitis and outcome-specific gut bacteria. Front Microbiol. 2021;12:742255. doi:10.3389/fmicb.2021.742255.
   PubMed Web of Science ®Google Scholar
• Zhao HJ, Luo X, Shi YC, Li JF, Pan F, Ren RR, Peng LH, Shi XY, Yang G, Wang J, et al. The efficacy of fecal microbiota transplantation for children with Tourette syndrome: A preliminary study. Front Psychiatry. 2020;11:554441. doi:10.3389/fpsyt.2020.554441.
   PubMed Web of Science ®Google Scholar
• Davar D, Dzutsev AK, McCulloch JA, Rodrigues RR, Chauvin JM, Morrison RM, Deblasio RN, Menna C, Ding Q, Pagliano O, et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science (New York, NY). 2021;371(6529):595–602. doi:10.1126/science.abf3363.
   Google Scholar
• Kaźmierczak-Siedlecka K, Daca A, Fic M, van de Wetering T, Folwarski M, Makarewicz W. Therapeutic methods of gut microbiota modification in colorectal cancer management - fecal microbiota transplantation, prebiotics, probiotics, and synbiotics. Gut Microbes. 2020;11(6):1518–1530. doi:10.1080/19490976.2020.1764309.
   PubMed Web of Science ®Google Scholar
• Chang CW, Lee HC, Li LH, Chiang Chiau JS, Wang TE, Chuang WH, Chen MJ, Wang HY, Shih SC, Liu CY, et al. Fecal microbiota transplantation prevents intestinal injury, upregulation of toll-like receptors, and 5-Fluorouracil/Oxaliplatin-induced toxicity in colorectal cancer. Int J Mol Sci. 2020;21(2). doi:10.3390/ijms21020386.
   Web of Science ®Google Scholar
• Wang Y, Wiesnoski DH, Helmink BA, Gopalakrishnan V, Choi K, DuPont HL, Jiang ZD, Abu-Sbeih H, Sanchez CA, Chang CC, et al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med. 2018;24(12):1804–1808. doi:10.1038/s41591-018-0238-9.
   PubMed Web of Science ®Google Scholar
• Jian Y, Zhang D, Liu M, Wang Y, Xu ZX. The impact of gut microbiota on radiation-induced enteritis. Frontiers Cellular Infect Microbiol. 2021;11:586392. doi:10.3389/fcimb.2021.586392.
   PubMed Web of Science ®Google Scholar
• Zhang J, Haines C, Watson AJM, Hart AR, Platt MJ, Pardoll DM, Cosgrove SE, Gebo KA, Sears CL. Oral antibiotic use and risk of colorectal cancer in the United Kingdom, 1989-2012: a matched case-control study. Gut. 2019;68(11):1971–1978. doi:10.1136/gutjnl-2019-318593.
   PubMed Web of Science ®Google Scholar
• Chen JF, Wu SW, Shi ZM, Hu B. Traditional Chinese medicine for colorectal cancer treatment: potential targets and mechanisms of action. Chin Med. 2023;18(1):14. doi:10.1186/s13020-023-00719-7.
   PubMed Web of Science ®Google Scholar
• Chen YX, Gao QY, Zou TH, Wang BM, Liu SD, Sheng JQ, Ren JL, Zou XP, Liu ZJ, Song YY, et al. Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study. Lancet Gastroenterol Hepatol. 2020;5(3):267–275. doi:10.1016/s2468-1253(19)30409-1.
   PubMed Web of Science ®Google Scholar
• Yu YN, Yu TC, Zhao HJ, Sun TT, Chen HM, Chen HY, An HF, Weng YR, Yu J, Li M, et al. Berberine may rescue Fusobacterium nucleatum-induced colorectal tumorigenesis by modulating the tumor microenvironment. Oncotarget. 2015;6(31):32013–32026. doi:10.18632/oncotarget.5166.
   PubMedGoogle Scholar
• Chen H, Ye C, Cai B, Zhang F, Wang X, Zhang J, Zhang Z, Guo Y, Yao Q. Berberine inhibits intestinal carcinogenesis by suppressing intestinal pro-inflammatory genes and oncogenic factors through modulating gut microbiota. BMC Cancer. 2022;22(1):566. doi:10.1186/s12885-022-09635-9.
   PubMed Web of Science ®Google Scholar
• Weng W, Goel A. Curcumin and colorectal cancer: An update and current perspective on this natural medicine. Semin Cancer Biol. 2022;80:73–86. doi:10.1016/j.semcancer.2020.02.011.
   PubMed Web of Science ®Google Scholar